Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 4

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 3(3)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06235151Phase 3Recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

Role: lead

NCT06377371Phase 4Recruiting

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

Role: collaborator

NCT06235099Phase 3Completed

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

Role: lead

NCT05204927Phase 3Active Not Recruiting

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Role: lead

NCT05653856Phase 2Completed

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Role: lead

NCT04334837Unknown

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Role: lead

All 6 trials loaded